Trials / Completed
CompletedNCT05369793
Clinical Study Evaluating the Safety and Efficacy of Roflumilast in Type 2 Diabetic Patients With Diabetic Neuropathy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Tanta University · Academic / Other
- Sex
- All
- Age
- 25 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of the side effects and efficacy of roflumilast on glycemic parameters, insulin resistance, oxidative and inflammatory markers in Type 2 diabetic patients with diabetic neuropathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alpha lipoic acid | Administration of alpha-lipoic acid 600mg plus vildagliptin/metformin combination (50/1000mg) orally once daily for 3 months. |
| DRUG | Roflumilast | Administration of 500 mcg plus vildagliptin/metformin combination(50/1000mg) orally once daily for 3 months. |
Timeline
- Start date
- 2022-08-01
- Primary completion
- 2023-10-10
- Completion
- 2023-10-10
- First posted
- 2022-05-11
- Last updated
- 2023-11-22
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT05369793. Inclusion in this directory is not an endorsement.